Handelsavisen
prelaunch
Companies 000538.SZ
00
000538.SZ Shenzhen Stock Exchange Unclassified

Yunnan Baiyao Group Co Ltd

¥49,47
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
88,3B CNY
P/E
EV / Rev
Div yield
5,35 %
Op margin
14,7 %
ROE
12,9 %
Net margin
12,5 %
Debt / equity
0,03
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Yunnan Baiyao Group Co Ltd operates in the health care sector, specifically within the pharmaceuticals industry, generating revenue through the sale of healthcare products and services.

Business. Yunnan Baiyao Group Co Ltd operates in the health care sector, specifically within the pharmaceuticals industry, generating revenue through the sale of healthcare products and services.

Classification20 %
SectorUnclassified
Generated · model-assisted
Sell-side consensus
BUY9 analysts
9 buy0 hold0 sell
Avg 12m price target70,01

Analyst recommendations

9 analysts · consensus Buy
Buy9
Hold0
Sell0
12-month price target
70,01
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
9 analysts · indicative
Ownership
not yet wired
Profitability
12,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 000538.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 000538.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Yunnan Baiyao Group Co Ltd operates in the health care sector, specifically within the pharmaceuticals industry, generating revenue through the sale of healthcare products and services.

    Classification20 %
    SectorUnclassified
    AI synthesis
    GENERATED

    Yunnan Baiyao maintains a conservative capital structure with a debt-to-equity ratio of 0.03 and a current ratio of 2.64, indicating strong short-term liquidity coverage. The company holds total equity of 40.04 billion CNY against total liabilities of 14.22 billion CNY. Despite the strong balance sheet, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting that cash and equivalents are lower than total debt obligations. The company generated 4.60 billion CNY in operating cash flow, which comfortably covers its capital expenditure of 480 million CNY, resulting in free cash flow of 1.04 billion CNY.

    Profitability metrics demonstrate efficient capital utilization, with a return on equity of 12.87% and a return on assets of 9.50%. The company trades at a price-to-earnings ratio of 16.84 and an EV/EBITDA of 14.57, reflecting a moderate valuation multiple relative to its earnings power. The price-to-book ratio stands at 2.17, indicating the market values the company's tangible assets at a premium. Operating income of 6.04 billion CNY on revenue of 41.19 billion CNY suggests a stable operating margin, supported by gross profit of 11.90 billion CNY.

    Segment and geographic revenue breakdowns are not provided in the available data, preventing a detailed analysis of revenue concentration or regional exposure. The analysis relies on consolidated financial figures, which show a broad revenue base of 41.19 billion CNY. Without segment data, it is not possible to assess the contribution of specific product lines or geographic markets to the overall financial performance.

    Historical growth trajectory data is absent from the input, limiting the ability to evaluate long-term revenue trends or earnings consistency. The current financial snapshot provides a static view of the company's performance, with net income of 5.15 billion CNY. The lack of historical period data prevents a year-over-year or quarter-over-quarter growth analysis, leaving the growth narrative reliant on current period metrics alone.

    Risk assessment indicates low dilution risk, supported by the fact that basic and diluted shares outstanding are identical at 1.78 billion shares. The key flag regarding negative net cash after debt subtraction warrants monitoring, as it may impact financial flexibility despite the low leverage ratio. The medium liquidity risk rating suggests potential constraints in meeting short-term obligations under stress scenarios, although the current ratio of 2.64 provides a buffer.

    Recent investor relations observations show strong analyst sentiment, with a mean recommendation of 1.78 (where 1 is strong buy) and a mean price target of 70.01 CNY, implying significant upside from the current market price of 48.65 CNY. The high price target of 82.20 CNY and low of 64.00 CNY indicate a consensus view of undervaluation. There are no hold ratings among the analysts, with 2 strong buys and 7 buys recorded, reflecting positive market expectations for the company's future performance.

    Key takeaways
    • Strong balance sheet with low leverage (debt-to-equity 0.03) and high current ratio (2.64) supports financial stability.
    • Analyst consensus is bullish with a mean price target of 70.01 CNY, suggesting 44% upside from the current price of 48.65 CNY.
    • Profitability is solid with ROE of 12.87% and ROA of 9.50%, indicating efficient use of assets and equity.
    • Negative net cash position after debt subtraction is a key risk flag despite low overall debt levels.
    • Low dilution risk is confirmed by identical basic and diluted share counts.
    • Lack of segment and historical data limits the depth of growth and concentration analysis.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥49,47
    Market cap
    ¥86.80B
    Enterprise value
    ¥87.97B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    19.1x
    P / B
    2.2x
    P / Tangible book
    2.2x
    Tangible book
    ¥40.04B
    Net cash
    -¥1.17B
    Current ratio
    2.6
    Debt / equity
    0.0
    ROA
    9.5%
    ROE
    12.9%
    Cash conversion
    89.0%
    CapEx / revenue
    -1.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Traditional Chinese Medicines
    low · llm_fanout_v2
    Wound Care Products
    low · llm_fanout_v2

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    3,19
    Predicted surprise
    -0,05
    Beat probability
    45 %
    Analysts
    9
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-08 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate3,18
    Revenueno estimateno estimate42,6B CNY
    Operating incomeno estimateno estimate5,9B CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution9 analysts
    Strong buy2
    Buy7
    Hold0
    Sell0
    Strong sell0
    12-month price target¥69,76 · Median ¥68,60
    Low ¥62,00High ¥82,20
    Operating income · consensus5,9B CNY
    EPS surprise
    −9,0 %
    reported vs consensus · miss
    Revenue surprise
    −3,3 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥64,00
    Mean¥70,01
    Median¥68,60
    High¥82,20
    Spot¥49,47
    +41.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin14,7 %Above median
    Net Margin12,5 %Above P75
    ROE12,9 %Above median
    Capex / Rev-1,2 %Above P75
    D/E0,03Above P75
    Cash Conv0,89Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Ev To Operating Income
      enterprise_value / operating_income
    Source documents
    • Yunnan Baiyao Group Co Ltd Market data — financials · 2026-07-08
    • Yunnan Baiyao Group Co Ltd Market data — analyst estimates · 2026-07-08
    • Yunnan Baiyao Group Co Ltd Market data — ESG · 2026-07-08

    Ownership & reference

    Leadership

    • Hongshen LiSenior Vice President
    • Ming DongPresident, Chief Executive Officer, Director
    • Shengli LiSenior Vice President

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    000538.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    PredictorBeat prob45 %Surprise-0,05Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage